MicroRNA-145 inhibits the malignant phenotypes of gastric carcinoma cells via downregulation of fascin 1 expression

MINGHUI XUE1, LUNDE ZHAO1, FANG YANG2, ZHENJUAN LI2 and GUANGYAN LI2

Departments of 1General Surgery and 2Gastroenterology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China

Received January 21, 2015; Accepted November 5, 2015

DOI: 10.3892/mmr.2015.4609

Abstract. MicroRNA (miR)-145 has been demonstrated to act as a tumor suppressor, and deregulation of fascin 1 (FSCN1) has been observed in several types of human malignancy, including gastric carcinoma. However, the molecular mechanism underlying the function of miR-145, specifically its targets in gastric carcinoma have yet to be fully elucidated. In the present study, downregulation of miR-145 and upregulation of FSCN1 was identified in gastric carcinoma cell lines, compared with normal gastric mucosal epithelial cells. A luciferase reporter assay demonstrated that miR-145 was able to bind to the 3'-untranslated region of FSCN1 mRNA. Overexpression of miR-145 led to a significant decrease in FSCN1 expression levels, whereas knockdown of miR-145 resulted in increased FSCN1 expression levels in gastric carcinoma cells. Furthermore, overexpression of miR-145 inhibited proliferation, migration and invasion in gastric carcinoma cells. Similar effects were also observed in gastric carcinoma cells transfected with FSCN1 small interfering RNA. In addition, overexpression of FSCN1 reversed the suppressive effects of miR-145 upregulation on proliferation, migration and invasion in gastric carcinoma cells, suggesting that FSCN1 is indeed involved in the miR-145-mediated malignant phenotype of gastric carcinoma cells. The present study revealed an anti-oncogenic role of miR-145 in gastric carcinoma via inhibition of FSCN1, and suggested that miR-145 may be used for the treatment of gastric carcinoma.

Introduction

Gastric cancer is one of the most common types of human cancer worldwide (1). Although significant progress has been achieved in recent years, the early diagnosis and treatment for gastric cancer is not yet satisfactory. Furthermore, gastric carcinoma is difficult to cure due to its heterogeneity, therefore the prognosis remains poor (1). Investigation into the molecular mechanisms underlying gastric carcinoma have begun to yield results (2).

MicroRNAs (miRs) are a type of small non-coding RNA, that are able to regulate various physiological and developmental processes by mediating the expression levels of their target genes, via direct binding to the 3'-untranslated region (3'-UTR) of their target mRNAs (3). Furthermore, miRs have been demonstrated to be associated with tumorigenesis and tumor progression. miRs can promote or inhibit the development and progression of human cancer (4,5). Deregulation of certain miRNAs, such as miR-10b, miR-29a, miR-145, miR-126, miR-133, miR-143, miR-148a, miR-218, miR-941, miR-1247 and miR-145, have been reported to be associated with gastric carcinoma (6-15). miR-145 has been shown to generally act as a tumor suppressor in numerous types of human cancers, such as colorectal cancer, gastric carcinoma, bladder cancer and glioma (14,16-20). Takagi et al (14) demonstrated that miR-145 was downregulated in the majority of the 43 gastric cancer tissue samples examined. Qiu et al (13) suggested that miR-145 suppressed the proliferation, migration, invasion and cell cycle progression of gastric cancer cells by targeting transcription factor Sp1. As one miRNA may target various mRNAs, other targets may also be involved in miR-145-mediated malignant phenotypes of gastric carcinoma cells.

The present study aimed to reveal the regulatory mechanism by which miR-145 mediates the malignant phenotype of gastric cancer cells, focusing on its target genes.

Materials and methods

Materials. Dulbecco's modified Eagle's medium (DMEM), TRizol reagent, fetal bovine serum (FBS), an miRNA Reverse Transcription kit, a SYBR Ex Taq kit, and Lipofectamine 2000 were purchased from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA). An miRNA Q-Polymerase Chain Reaction (PCR) Detection kit was purchased from GeneCopoeia (Rockville, MD, USA). Mouse anti-human FSCN1 monoclonal antibody (dilution, 1:500; cat. no. ab49815), mouse anti-human GAPDH monoclonal antibody (dilution, 1:500; cat. no ab184531) and rabbit anti-mouse
IgG secondary antibody (dilution, 1:10,000; cat. no. ab6728) were purchased from Abcam (Cambridge, UK). An Enhanced Chemiluminescence (ECL) kit was purchased from Pierce Biotechnology, Inc. (Rockford, IL, USA). A Quick-Change Site-Directed Mutagenesis kit was purchased from Agilent Technologies, Inc. (Santa Clara, CA, USA). A psiCHECK 2 vector was purchased from Promega Corporation (Madison, WI, USA), and a Migration Detection kit I was purchased from BD Biosciences (San Jose, CA, USA).

Cell culture. Five human gastric cancer cell lines, BGC823, SGC7901, SNU5, HGC27 and AGS cells, as well as the GES1 normal gastric mucosa epithelial cell line were purchased from the Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in DMEM supplemented with 10% FBS, 100 IU/ml penicillin (Beyotime Institute of Biotechnology, Wuhan, China) and 100 mg/ml streptomycin (Beyotime Institute of Biotechnology) incubated at 37°C in a humidified chamber containing 5% CO₂.

Reverse transcription-quantitative (RT-q)PCR assay. Total RNA was extracted using TRIzol reagent, according to the manufacturer's instructions. For the detection of the mRNA expression of FSCN1, a RevertAid First-Strand cDNA Synthesis kit (Thermo Fisher Scientific, Inc., Pittsburgh, PA, USA) was used to reverse transcribe RNA into cDNA, according to the manufacturer's instructions. mRNA expression was detected using the SYBR Green qPCR Assay kit, according to the manufacturer's protocol. GAPDH served as an endogenous reference. The specific primers were as follows: FSCN1 forward, 5'-CCAGGGTATGGG CCTGTCTG-3'; and reverse, 5'-GGAGCGAGATCCCTC CAAAAT-3'; and reverse, 5'-GCCGTGTGTGTCATCTT CATGG-3'. The reaction conditions were as follows: 95°C for 3 min, followed by 40 cycles of denaturation at 95°C for 15 sec and annealing/elongation at 60°C for 30 sec. The PCR reaction was performed on a 7500 Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). For the detection of miR-145 expression, a miRNA Reverse Transcription kit was used to reverse transcribe RNA into cDNA, according to the manufacturer's instructions. The expression levels of miR-145 were determined using a miRNA Q-PCR Detection kit, following the manufacturer's protocol. The U6 small nuclear RNA was used for normalization. The relative mRNA and miRNA expression levels were analyzed by the 2^−ΔΔCq method.

Western blotting. Western blotting was used to examine relative protein expression levels. Briefly, total protein was extracted using radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology), and separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Beyotime Institute of Biotechnology), and then transferred onto a polyvinylidene difluoride (PVDF) membrane (EMD Millipore, Billerica, MA, USA). The PVDF membrane was then incubated with Tris-buffered saline with Tween 20 (Beyotime Institute of Biotechnology) containing 5% milk at room temperature for 3 h for blocking. The membrane was subsequently incubated with mouse anti-FSCN1, and mouse anti-GAPDH primary antibodies at room temperature for 3 h. Following washing with phosphate-buffered saline (PBS) with Tween 20 three times, the PVDF membrane was incubated with rabbit anti-mouse secondary antibodies at room temperature for 1 h. Chemiluminescence detection was performed using the ECL kit. The relative protein expression levels were analyzed using Image-Pro plus software 6.0 (Media Cybernetics, Inc., Rockville, MD, USA), and the values were presented as the density ratio compared with GAPDH.

Transfection. For functional analysis, transfection was performed using Lipofectamine 2000 according to the manufacturer's instructions. For FSCN1 functional analysis, cells were transfected with FSCN1-specific small interfering (si)RNA (produced by Auragene Biosciences, Changsha, China) or pcDNA3.1-FSCN1 plasmids (produced by Auragene Biosciences). For miR-145 functional analysis, cells were transfected with scrambled miRNA (negative control), miR-145 mimics or miR-145 inhibitor (all produced by Auragene Biosciences).

Luciferase reporter assay. Following to the manufacturer's instructions, a mutant type 3'-UTR of FSCN1 was generated using the Quick-Change Site-Directed Mutagenesis kit. The wild or mutant type 3'-UTR of FSCN1 was then inserted into the psiCHECK2 vector using the restriction endonucleases, XhoI and NotI at the multiple cloning regions in the psiCHECK2 vector. A luciferase reporter assay was subsequently performed. Briefly, the cells were cultured (37°C in a humidified chamber containing 5% CO₂) to 70% confluence (70%) and separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The supernatant was removed, and 100 µl of 1x10⁴ cells/well were plated in a 96-well plate, and incubated for 48 h at 37°C in an atmosphere containing 5% CO₂. The supernatant was removed, and 100 µl of dimethyl sulfoxide was added to dissolve the precipitation. The absorbance was detected at 492 nm using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Renilla luciferase activity was normalized to firefly luciferase activity.

MTT assay. An MTT assay (Beyotime Institute of Biotechnology) was performed to examine cell proliferation. Briefly, for each group (cells transfected with miR-145 mimics, FSCN1 siRNA or co-transfected with miR-145 mimics and FSCN1 plasmid), 1x10⁴ cells/well were plated in a 96-well plate, and incubated for 48 h at 37°C in an atmosphere containing 5% CO₂. To assess cell proliferation, 10 µl MTT (5 mg/ml) was added to each well, and further incubated for 4 h at 37°C in an atmosphere containing 5% CO₂. The supernatant was removed, and 100 µl of dimethyl sulfoxide was added to dissolve the precipitation. The absorbance was detected at 570 nm using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

Scratch assay. A scratch assay was performed to determine the cell migratory capacity in each group. Cells were cultured to full confluence (70%) at 37°C in a humidified chamber containing 5% CO₂, and a scratch wound of ~1 mm width was created with a plastic scriber. The cells were then washed with PBS, and cultured at 37°C in an atmosphere containing...
5% CO₂ for 48 h. The cells in each group were then fixed and observed under a microscope (CKX41; Olympus Corporation, Tokyo, Japan).

**Invasion assay.** A Transwell assay was conducted for invasion analysis (using Matrigel-coated polyethylene terephthalate membrane chambers; BD Biosciences), and a cell suspension containing 5x10⁵ cells/ml was prepared in serum-free DMEM. A total of 300 µl cell suspension was then added into the upper chamber and 500 µl RPMI-1640 (Invitrogen: Thermo Fisher Scientific, Inc.) supplemented with 10% FBS was added into the lower chamber. Following incubation for 24 h, non-invading cells as well as the matrix gel (BD Biosciences) on the interior of the inserts was removed using a cotton-tipped swab. Invasive cells on the lower surface of the membrane were stained using 0.1% crystal violet (Beyotime Institute of Biotechnology) for 20 min, and then rinsed with water and dried. Five fields were randomly selected, and cell number was counted under a microscope (CKX41; Olympus Corporation).

**Statistical analysis.** The values are presented as the mean ± standard deviation of three independent experiments. Statistical analysis of differences was performed by one-way analysis of variance using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Expression levels of miR-145 and FSCN1 in gastric carcinoma cells.** RT-qPCR was conducted to determine the expression level of miR-145 in five common gastric cancer cell lines,
miR-145 suppresses FSCN1 expression by binding to the 3'-UTR of FSCN1 mRNA in gastric carcinoma cells. The putative seed sequences for miR-145 at the 3'-UTR of FSCN1 are shown in Fig. 2A. To clarify whether or not miR-145 was able to bind to the 3'-UTR of FSCN1 mRNA, a wild type and mutant type FSCN1 3'-UTR were generated (Fig. 2A), and a luciferase reporter assay was subsequently performed in the AGS gastric carcinoma cells. Luciferase activity levels were significantly reduced in AGS cells with the wild type 3'-UTR of FSCN1 mRNA co-transfected with miR-145 mimics; however, luciferase activity levels did not change in AGS cells with mutant type 3'-UTR of FSCN1 mRNA co-transfected with miR-145 mimics, compared with the control group (Fig. 2B), indicating that FSCN1 is a direct target gene of miR-145. It was further investigated whether miR-145 could affect the expression levels of FSCN1 in gastric carcinoma cells. Following transfection with miR-145 mimics and inhibitor into AGS cells, RT-qPCR was performed to determine the changes in miR-145 expression levels. As shown in Fig. 2C, transfection with miR-145 mimics led to significant upregulation of miR-145 expression levels, whereas transfection with an miR-145 inhibitor resulted in reduced miR-145 expression levels in AGS cells. In addition, the protein expression levels of FSCN1 were reduced in AGS cells overexpressing miR-145, and these expression levels were increased following knockdown of miR-145 (Fig. 2D). Therefore, the results suggest that miR-145 negatively regulates the protein expression of FSCN1 in AGS gastric carcinoma cells, perhaps by directly binding to the 3'-UTR of FSCN1 mRNA.

Effects of miR-145 and FSCN1 on proliferation, migration and invasion in gastric carcinoma cells. The roles of miR-145 and FSCN1 in the regulation of malignant phenotypes of gastric cancer cells were further investigated. AGS cells were transfected with miR-145 mimics or FSCN1 siRNA. Post-transfection, the expression levels of FSCN1 in each group were quantified, and showed that transfection
with miR-145 mimics and FSCN1 siRNA reduced FSCN1 expression levels (Fig. 3A). Subsequently, cell proliferation, migration and invasion analyses were performed. As shown in Fig. 3B-D, overexpression of miR-145 inhibited proliferation, migration and invasion, similar to the effects of FSCN1 knockdown.

FSCN1 overexpression reverses the inhibitory effects of miR-145 upregulation on proliferation, migration and invasion in gastric carcinoma cells. To further clarify whether FSCN1 was involved in miR-145-mediated malignant phenotypes of gastric carcinoma cells, AGS cells were transfected with miR-145 mimics, or co-transfected with miR-145 mimics and pcDNA3.1-FSCN1 plasmids. The protein expression levels of FSCN1 were subsequently determined in each group. As shown in Fig. 4A, co-transfection with miR-145 mimics and FSCN1 plasmids reversed the inhibitory effect on FSCN1 expression in AGS cells compared with transfection with miR-145 mimics alone. The proliferation, migration and invasion of these two groups were also compared. As shown in Fig. 4B-D, overexpression of FSCN1 reversed the suppressive effects of miR-145 upregulation on proliferation, migration and invasion in AGS cells, indicating that FSCN1 is indeed involved in miR-145-mediated malignant phenotypes of gastric cancer cells.

Discussion

MicroRNAs inhibit the protein expression of their target genes by binding to the 3'-UTR of target mRNAs based on sequence complementarity (3). The present study identified FSCN1 as a target of miR-145 in gastric carcinoma cells, and demonstrated that miR-145 was downregulated, whereas FSCN1 was upregulated in gastric carcinoma cell lines, as compared with normal gastric mucosal epithelial cells. Furthermore, the results suggested that the suppressive effects of miR-145 on proliferation, migration and invasion in gastric carcinoma cells occur partly through direct inhibition of FSCN1 expression. Deregulation of miRs has been demonstrated to be associated with tumorigenesis and tumor progression (21). In the present study, miR-145 was demonstrated to be significantly downregulated in gastric carcinoma cell lines, as compared with normal gastric mucosal epithelial cells, results which were concordant with those of previous studies that demonstrated that the expression levels of miR-145 were reduced in gastric carcinoma tissue samples and cell lines (13,14). Downregulated expression levels of miR-145 have also been reported in other types of cancer including glioma, colorectal cancer, and esophageal squamous cell carcinoma (22-25). It has been reported that miR-145 targets the transcription factor SP1, the knockdown of which inhibits the expression of matrix
metalloproteinase-9 and cyclin D1 associated with cell growth and invasion in gastric carcinoma cells (13). Furthermore, overexpression of miR-145 induced higher sensitivity of gastric cancer cells to 5-fluorouracil, and the possible candidate targets of miR-145 were identified to be insulin receptor substrate-1 and β-actin (14). The results of the present study demonstrated that overexpression of miR-145 inhibited cell proliferation, migration and invasion in gastric carcinoma cells. However, the molecular mechanism by which miR-145 mediates the malignant phenotypes of gastric carcinoma cells remains to be elucidated.

Furthermore, the results of the present study demonstrated that FSCN1 was a target gene of miR-145 in gastric cancer cells, and was negatively regulated by miR-145. FSCN1, a member of the FSCN family of actin-binding proteins, has an important role in the organization of F-actin into parallel bundles and in the formation of filopodia (26,27). In addition, FSCN1 participates in the regulation of cellular interactions, adhesion and motility, and overexpression of FSCN1 is associated with cancer metastasis by promoting cell motility (27,28). Recently, deregulation of FSCN1 was shown to occur in gastric carcinoma (29). Tsai et al (30) demonstrated that >50% of the 60 poorly differentiated gastric adenocarcinoma tissue samples exhibited moderate or strong FSCN1 expression, and higher expression levels of FSCN1 were directly correlated with more-advanced cancer stages, and inversely correlated with survival rate, suggesting that aberrant upregulation of FSCN1 may be involved in the progression of gastric adenocarcinoma (30). In the present study, the results demonstrated that the expression levels of FSCN1 were upregulated in gastric carcinoma cells, compared with normal gastric mucosal epithelial cells, and knockdown of FSCN1 inhibited AGS cell proliferation, migration and invasion. A previous study also showed that inhibition of FSCN1 expression suppressed the proliferation and metastasis of gastric carcinoma cells (31). In addition, FSCN1 was involved in the transforming growth factor-β1-induced invasion and metastasis in gastric carcinoma (32).

The results of the present study demonstrated that FSCN1 was involved in miR-145-mediated AGS cell proliferation, migration and invasion. The association between miR-145 and FSCN1 has also been demonstrated in several other types of cancer (23,33). For instance, miR-145 was found to suppress tumor cell invasion and migration by targeting FSCN1 in breast cancer cells (33). In addition, miR-145 inhibited proliferation and invasion via the suppression of FSCN1 in esophageal squamous cell carcinoma cells (24). The expression of FSCN1 is also mediated by other miRs in several types of cancer. For example, Akunama et al (34) demonstrated that knockdown of FSCN1 inhibited the proliferation and invasion of esophageal squamous cell carcinoma cells, similar to the effect of miR-133a overexpression, and identified FSCN1 as a target of miR-133a. Another study suggested that upregulated miR-451 in colon cancer cells may inhibit AMP-activated protein kinase from activating mammalian target of rapamycin complex 1, which mediates FSCN1 expression and cancer cell progression (35).

In conclusion, the results of the present study revealed an anti-oncogenic role of miR-145 in gastric cancer via direct inhibition of its target gene FSCN1. Therefore, the present study suggested that miR-145 may be used for the treatment of gastric carcinoma.

References


